Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 1/20 | 0.52 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737457 | 1.00 | FABP7 (0.52) | FABP7FABP5CA1CA2ALDH1A1 | |
| SCHEMBL10119921 | 0.87 | FABP7 (0.62) | FABP7FABP5CA1CA2ALDH1A1 | |
| SCHEMBL6737713 | 0.87 | FABP7 (0.62) | FABP7FABP5CA1CA2ALDH1A1 | |
| SCHEMBL14827600 | 0.80 | FABP7 (0.53) | FABP7FABP5ALDH1A1HPGDHTT | |
| SCHEMBL14827601 | 0.80 | FABP7 (0.53) | FABP7FABP5ALDH1A1HPGDHTT | |
| SCHEMBL13198700 | 0.79 | FABP7 (0.52) | FABP7FABP5ALDH1A1HPGDHTT | |
| SCHEMBL13688299 | 0.78 | FABP7 (0.51) | FABP7FABP5ALDH1A1HPGDHTT | |
| SCHEMBL10119916 | 0.78 | FABP7 (0.51) | FABP7FABP5ALDH1A1HPGDHTT | |
| SCHEMBL10119915 | 0.78 | FABP7 (0.51) | FABP7FABP5ALDH1A1HPGDHTT | |
| SCHEMBL6737480 | 0.78 | FABP7 (0.51) | FABP7FABP5ALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100152438-A1 | AMPHIPHILIC MOLECULAR MODULES AND CONSTRUCTS BASED THEREON | COVALENT PARTNERS LLC | 2010-06-17 | — | — | US | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-7563890-B2 | Amphiphilic molecular modules and constructs based thereon | COVALENT PARTNERS, LLC (US) | 2009-07-21 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152438-A1 | AMPHIPHILIC MOLECULAR MODULES AND CONSTRUCTS BASED THEREON | ANXA6, THEM6, ANXA5 | FABP7 90/4885FABP5 126/4885CA1 2953/4885 |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | FABP7 4149/4885FABP5 3342/4885CA1 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.